Cancer News: Lung

Adding radiation to chemotherapy may improve some lung cancer outcomes

For patients with limited metastatic non-small cell lung cancer (NSCLC), adding radiation therapy to chemotherapy with may curb disease progression dramatically.

Seeking clarity on CT scans after lung cancer surgery

A trial did not show a difference in overall survival (OS) between patients who received computed tomography (CT) scans as part of their follow-up, and those who did not.

Pembrolizumab: A new treatment option for metastatic lung cancer

Pembrolizumab – an anti PD1 therapy- is approved by FDA for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).

Short-term training improves aerobic performance in lung cancer

High-intensity interval training (HIIT) in patients with resectable non-small cell lung cancer (NSCLC) before surgey improves aerobic performance.

Atezolizumab got approved for non-small cell lung cancer

FDA approved atezolizumab treatment for non-small cell lung cancer (NSCLC) patients whose disease progressed during or following platinum-containing chemotherapy.

Checkpoint inhibitors benefit survival in non-small-cell lung cancer

Atezolizumab, can prolong survival rate in patients with non-small-cell lung cancer regardless their PD-L1 expression.

New treatment option for patients with advanced lung cancer

Pembrolizumab can be the alternative option for first line treatment of patients with advanced lung cancer and high PD-L1 expression.

Intense radiation scheme can help non-small cell lung cancer patients

Hypo-fractionated radiation has similar outcomes with conventional one for non-small lung cancer patients and milder side-effects, despite its shorter duration.

Stereotactic body radiotherapy prolongs survival in lung cancer patients

Stereotactic body radiotherapy (SBRT) can improve outcomes in patients with non-small cell lung cancer (NSCLC), according to new research.

Brain metastasis in lung cancer: is brain radiotherapy beneficial?

Similar quality of life for lung cancer patients with brain metastasis treated with whole brain radiotherapy compared to those who didn’t, an analysis shows.

Olanzapine prevented chemotherapy-induced nausea

Patients undergoing chemotherapy experienced no nausea or vomiting after including olanzapine to their prophylactic drug combination, a phase 3 study reveals.

A diagnosis of high cholesterol led to increased cancer survival

A diagnosis of high cholesterol led to reduced mortality and improved survival in lung, breast, prostate and bowel cancer, a new researches reveals.

Immunotherapy Keytruda prolonged survival in lung-cancer patients

Merck’s Keytruda immunotherapy prolonged survival without disease progression in advanced lung cancer patients, the results of a large trial show.

Skin cancer combo shows evidence against lung cancer

Novartis's drug combination of Tafinlar and Mekinist increased progression-free survival in lung cancer patients almost up to 10 months, said the company.

Is chemotherapy beneficial for non-small cell lung cancer patients?

A new large analysis showed that patients with stage IB non-small cell lung cancer lived longer with adjuvant chemotherapy treatment.

Surgery improved survival in lung cancer patients

Patients with late-stage, non-small cell lung cancer who had surgery lived longer than those who didn’t, a new data analysis reveals.

Better quality of life after surgery for mesothelioma patients

Patients with an aggressive type of cancer called malignant pleural mesothelioma improved their quality of life after surgery, a survey reveals.

Early screening can save lives in lung cancer

Screening patients with a high risk of developing lung cancer can identify early stage disease, improving greatly their survival rates.

Palliative care helps families facing cancer

Palliative care showed to improve caregivers’ quality of life and mood creating a powerful positive feedback loop in families facing cancer.

Older lung cancer patients live longer after surgery

Older lung cancer patients live longer after cancer surgery, almost 2 years longer than the benchmark 5-year survival rate, a new analysis shows.

Nivolumab gets EU approval for lung and kidney cancers

EU regulators have approved nivolumab as a treatment against advanced or metastatic non-squamous non-small cell lung cancer and advanced renal cell carcinoma.

US approval of crizotinib for metastatic non-small cell lung cancer

US regulators approved crizotinib capsules for the treatment of metastatic non-small cell lung cancer.

Everolimus gets FDA approval for another indication

Everolimus got approved by the FDA for the treatment of inoperable, locally advanced or metastatic neuroendocrine tumors of gastrointestinal or lung origin.

Should lung and esophageal cancer survivors do more PET scans?

Lung and esophageal cancer survivors may not get benefit from radioactive imaging tests used to diagnose cancer recurrence, a new study reveals.

Osimertinib gets EU approval for non-small cell lung cancer

EU regulators approved osimertinib for the treatment of adult patients with a specific mutation-positive non-small cell lung cancer.

Ramucirumab: EU approval for lung and metastatic colorectal cancer

Ramucirumab received approval by the European Commission to be used as a treatment for advanced non-small cell lung cancer and metastatic colorectal cancer.

Afatinib appears effective in lung cancer patients

Afatinib improved progression-free survival and response in non-small cell lung cancer patients with common epidermal growth factor mutations and brain metastases.

Afatinib seems promising for EGFR-mutated lung cancer

A study comparing afatinib than gefitinib as first-line treatment in patients with advanced lung cancer showed the effectiveness of afatinib.

Afatinib induces better responses in EGFR-mutated lung cancer

Afatinib appears to be more effective than gefitinib for the treatment of patients with EGFR-activating mutations in advanced lung cancer, a new study shows.

Pembrolizumab: beneficial for more lung cancer patients

The immunotherapy drug pembrolizumab could benefit patients with refractory lung cancer selected for PD-L1 expression, a new study shows.

Login to your account

Did you forget your password?